Evidence map›Paper›PMID 29177615›Full record

ArticleInternational journal of hematology2018

ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.

Suguru Uemura, Noriyuki Nishimura, Daiichiro Hasegawa, Akemi Shono, Kimiyoshi Sakaguchi, Hisayuki Matsumoto, Yuji Nakamachi, Jun Saegusa, Takehito Yokoi, Teppei Tahara and 11 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. [Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion: a case report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 1 country.

Suguru UemuraDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan. sgr3u31@yahoo.co.jp.
Noriyuki NishimuraDepartment of Pediatrics, Kobe University, Graduate School of Medicine, Kobe, Japan.
Daiichiro HasegawaDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Akemi ShonoDepartment of Pediatrics, Kobe University, Graduate School of Medicine, Kobe, Japan.
Kimiyoshi SakaguchiDepartment of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hisayuki MatsumotoDivision of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Yuji NakamachiDivision of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Jun SaegusaDivision of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Takehito YokoiDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Teppei TaharaDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Akihiro TamuraDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Nobuyuki YamamotoDepartment of Pediatrics, Kobe University, Graduate School of Medicine, Kobe, Japan.
Atsuro SaitoDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Aiko KozakiDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Kenji KishimotoDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Toshiaki IshidaDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Nanako NinoDepartment of Pediatrics, Kobe University, Graduate School of Medicine, Kobe, Japan.
Satoru TakafujiDepartment of Pediatrics, Kobe University, Graduate School of Medicine, Kobe, Japan.
Takeshi MoriDepartment of Pediatrics, Kobe University, Graduate School of Medicine, Kobe, Japan.
Kazumoto IijimaDepartment of Pediatrics, Kobe University, Graduate School of Medicine, Kobe, Japan.
Yoshiyuki KosakaDepartment of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Minatojima Minamimachi 1-6-7, Chuo-ku, Kobe, 650-0047, Japan.
Kobe Children's Hospital · JPKobe University · JPKobe University Hospital · JPHamamatsu University School of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ETV6-ABL1 fusion is a rare but recurrent oncogenic lesion found in childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), without an established chromosomal abnormality, and is associated with poor outcome. In ETV6-ABL1-positive cases, an in-frame fusion produced by a complex rearrangement results in constitutive chimeric tyrosine kinase activity. Monosomy 7 is also a rare and unfavorable chromosomal abnormality in childhood BCP-ALL. Here, we report a 14-year-old female BCP-ALL patient with ETV6-ABL1 fusion combined with monosomy 7. She was admitted to our hospital because of persistent fever. Bone marrow nuclear cell count on admission was 855,000/µL with 90.0% blastic cells of lymphoid morphology. Blasts were positive for CD10, CD19, CD20, CD34, cyCD79a, cyTdT, HLA-DR, and CD66c, had a karyotype of 45, XX, - 7 [18/20] and a split signal for ABL1 FISH probe (92.7%), and were sensitive to tyrosine kinase inhibitors, imatinib and dasatinib, in vitro. ETV6-ABL1 fusion transcript was identified by whole transcriptome sequencing and confirmed by RT-PCR. She was treated with the high-risk protocol based on ALL-BFM 95, achieved complete remission (CR) after induction chemotherapy, and maintained CR for 4 months. To our knowledge, this is the first report of ETV6-ABL1 fusion combined with monosomy 7 in childhood BCP-ALL.

Indexed as

AdolescentChromosome DeletionChromosomes, Human, Pair 7DasatinibETS Translocation Variant 6 ProteinFemaleGene FusionGene RearrangementHumansImatinib MesylateInduction ChemotherapyLeukemia, B-CellMaintenance ChemotherapyOncogene Proteins, FusionOncogene Proteins v-ablPrecursor B-Cell Lymphoblastic Leukemia-LymphomaDasatinibETS Translocation Variant 6 ProteinImatinib MesylateOncogene Proteins, FusionOncogene Proteins v-ablProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins c-etsRepressor ProteinsETV6–ABL1Monosomy 7Ph-like ALL

Identifiers

PMID29177615
OpenAlexW2770679231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.